Skip to content
Parker Institute for Cancer Immunotherapy
Search
Search Close

Cécile Alanio, MD, PhD

Parker Bridge Fellow

Biography

Cécile is a former postdoctoral researcher in John Wherry’s lab. There, she took a translational approach to studying samples from COVID patients, as well as patients with pancreatic ductal adenocarcinoma (PDAC), glioblastoma, lymphoma, and patient who had undergone CAR T therapy. She is an independent Parker Bridge Fellow and Senior Scientist in the Immunity and Cancer unit (U932) and the Deputy Director of the Clinical Immunology Laboratory at the Institut Curie, Paris, France. Her T Cell Inspection (TCI) team studies T cell biology in human health and disease. Her focus is on cytomegalovirus (CMV) and transposable element (TE) latent infections, COVID-19, CAR T cell profiling, as well as thymic, lung and glioblastoma tumors. Cécile is an active collaborator of the Wherry Lab, the University of Pennsylvania, and the Parker Institute for Cancer Immunotherapy (PICI).

Education & Training

  • 2011: Université Paris 5, Paris, France, MD, Medicine
  • 2015: Institut Pasteur, Paris, France, Ph.D., Immunology

Awards & Honors

  • 2019: Parker Bridge Fellow
  • 2018: Philippe Foundation Award
  • 2017 : Institut National Cancer Association, support for training young doctors in translational research in oncology (Postdoc)
  • 2017: Fondation Bettencourt Schueller Young Researcher Award
  • 2017: Project granted with Seal of Excellence at EU H2020 Marie Curie Individual (Global) Fellowship (TURBO project)
  • 2016: Awarded among the 300 best talents 2016 L’Oréal-UNESCO Pour les Femmes et la Science
  • 2011: Institut National Cancer Association, support for training young doctors in translational research in oncology (PhD)
  • 2008: Institut National Cancer Association, support for training young doctors in translational research in oncology (Master)